Scarica l'app Stockscreener
67.62
5.60%
3.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Baird lifts Mirum Pharmaceuticals, Inc. (MIRM) price target on Bluejay Therapeutics acquisition - MSN
The week in pharma: action, reaction and insight – week to December 12 - The Pharma Letter
Eventide Asset Management LLC Has $134.22 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by BVF Inc. IL - MarketBeat
Boone Capital Management LLC Has $32.64 Million Stock Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Rx Rundown: Pfizer, Mirum Pharmaceuticals, Novartis and more - Medical Marketing and Media
Mirum Pharmaceuticals stock price target raised to $110 by Raymond James - Investing.com Canada
Baird Lifts Mirum Pharmaceuticals, Inc. (MIRM) Price Target on Bluejay Therapeutics Acquisition - Insider Monkey
Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition - Insider Monkey
What is HC Wainwright's Forecast for MIRM FY2025 Earnings? - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2025 - BioSpace
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback - Yahoo Finance
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Mirum Pharmaceuticals (Nasdaq: MIRM) approves stock option and RSU inducement grants for 8 new hires - Stock Titan
Mirum Pharmaceuticals stock price target raised to $100 by Leerink - Investing.com Canada
Trading Systems Reacting to (MIRM) Volatility - news.stocktradersdaily.com
Baird Maintains Mirum Pharmaceuticals (MIRM) Outperform Recommendation - Nasdaq
Mirum adds to liver disease pipeline with Bluejay takeout: Deals Report - BioCentury
One Peninsula drug maker to buy another for up to $820 million around drug cut by Novartis - The Business Journals
Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says - marketscreener.com
Mirum Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald - Yahoo Finance
Mirum to buy Bluejay for up to $820m in rare liver disease push - Yahoo Finance
Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $95 From $81, Keeps Overweight Rating - marketscreener.com
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Jump Financial LLC - MarketBeat
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - BioSpace
Five things for pharma marketers to know for Tuesday, December 9, 2025 - Medical Marketing and Media
Baird raises Mirum Pharmaceuticals stock price target to $88 on Bluejay acquisition - Investing.com Canada
Mirum to acquire Bluejay for $620 million, adding HDV treatment By Investing.com - Investing.com Canada
Mirum Pharma to buy Bluejay Therapeutics for up to $820 million - WTVB
Mirum Adds To Rare Liver Disease Portfolio With Bluejay Acquisition - Citeline News & Insights
Mirum Pharmaceuticals stock rises as Morgan Stanley reiterates Overweight rating - Investing.com Canada
Mirum Pharmaceuticals, Inc. (MIRM) Bluejay Therapeutics, Inc.,M&A CallSlideshow (NASDAQ:MIRM) 2025-12-08 - Seeking Alpha
MIRM: Acquisition brings a breakthrough hepatitis delta therapy, expanding rare disease leadership - TradingView
Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay - BioPharma Dive
Mirum Pharmaceuticals, Inc. entered into a definitive agreement to acquire Bluejay Therapeutics, Inc for $820 million. - marketscreener.com
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' - MSN
Latham & Watkins Advises Bluejay Therapeutics in US$620 Million+ Acquisition by Mirum Pharmaceuticals - Latham & Watkins LLP
Mirum Pharma to buy Bluejay Therapeutics for up to $820M - Axios
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Gl - pharmiweb.com
Mirum Pharmaceuticals To Acquire Bluejay Therapeutics In Rare Liver Disease Expansion - Nasdaq
Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug - marketscreener.com
Mirum Pharmaceuticals to Acquire Bluejay Therapeutics - Contract Pharma
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics - marketscreener.com
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million - TradingView — Track All Markets
Mirum to acquire Bluejay for $620 million, adding HDV treatment - Investing.com
Mirum Pharmaceuticals enters into definitive agreement to acquire Bluejay Therapeutics - marketscreener.com
Mirum Pharmaceuticals (NASDAQ: MIRM) to acquire Bluejay Therapeutics, adds HDV drug brelovitug and $200M PIPE - Stock Titan
Mirum Pharmaceuticals (MIRM) up 1.3% since last earnings report: Can it continue? - MSN
Affinity Asset Advisors LLC Cuts Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
How geopolitical risks impact Mirum Pharmaceuticals Inc. (08D) stockWeekly Earnings Recap & AI Driven Stock Price Forecasts - Newser
How Mirum Pharmaceuticals Inc. (08D) stock responds to job market shiftsJuly 2025 Trends & Consistent Profit Trade Alerts - Newser
0.42%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):